Titlebook: Indications for Heart Valve Replacement by Age Group; Carlos Gomez-Duran,George J. Reul Book 1989 Kluwer Academic Publishers 1989 Bypass.a

感激小女

ally, the findings indicate, if pediatric patients receive anticoagulation following mechanical valve replacement, it is well accepted and results in few complications. If children are not anticoagulated, complications arise. Conflicting results regarding the efficacy of PERSANTINE® and the use of aspirin vs.978-1-4684-6902-8978-1-4684-6900-4

兴奋过度

树木中

St. Jude Medical® Cardiac Valve Experience in Infants and Childrenrfarin, often in combination with sulfinpyrazone or dipyridamole. There have been 3 episodes of thromboembolism, all occurring in patients with suboptimal anticoagulation. We conclude that: 1) results from ST. JUDE MEDICAL cardiac valve replacement in the aortic position or in the mitral position wi

羞辱

Thromboembolic Complications in Pediatric Patients Undergoing Valve Replacement with the St. Jude Me a thrombosed mitral prosthesis in a 2-year-old child who survived emergency reoperation. There were 2 further instances of thromboembolism in 2 other children. This experience determined a change in policy, reinstituting the use of anticoagulants.

废止

Long-Term Results of Valvular Replacement in Pediatric Patientsars, 90.2% of the patients are free of complications due to anticoagulants. There are no significant differences in survival between biological and mechanical prostheses. We conclude that valvular replacement in children does not offer greater risks or complications than in adults. Owing to accelera

addition

职业拳击手

Prospective Randomized Study of the St. Jude Medical®, BjÖrk-Shiley®, and Starr-Edwards® 6120 Valve rate is significantly different (p < 0.05) at 5 years with 87.6 ± 4.5% for Group A vs. 77.4 ± 6% for Group B, and at 7 years with 83.4 ± 6.5% for Group A vs. 73.2 ± 7.2% for Group B. In conclusion, in the mitral position, the ST. JUDE MEDICAL prosthesis gives a significant benefit compared to BJÖRK

Middle-Ear

Nine Years Experience with 1287 Carpentier-Edwards® Porcine Bioprostheses(1.3%), 5 AVR patients (1%), and 4 combined AVR/MVR patients (4%). Primary valve failure occurred in 20 MVR (3%) and 18 AVR cases (2%). Endocarditis has occurred in 15 patients (1.1%). Gated scans (6 to 12 months postoperative) have shown stable or improved left ventricular function. Endo cardiogram

令人心醉

Robust

Midterm Follow-Up of the Bioimplant™ (Liotta) Heart Valvec valve replacement (DVR). The operative mortality was 8.2% (AVR 5.8%, MVR 10%, DVR 9%). The 236 operative survivors were followed over a period of 3 months to 4 years. Actuarial analysis of late results indicates an expected survival rate at 4 years of 92.2 ± 2.7% for the whole group (AVR 96%, MVR